Atisama Therapeutics (formerly Rage Bio) (“Atisama” or the “Company”), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. Bernard Coulie as Chair of the Board of Directors.
RB042 Phase 1 Clinical Update
The RB042 Phase 1 study (RB042_1001; NCT07285122), evaluating RB042 in healthy volunteers and healthy smokers, has advanced to multi-dose ascending (MAD) cohorts, and continues to demonstrate safety and tolerability. Three of four single ascending dose (SAD) cohorts are complete, and the first MAD cohort has been initiated, with higher-dose cohorts expected to readout in H2 2026.
“RB042 clinical progress is tracking to plan. Safety and tolerability across three SAD cohorts have supported advancement into MAD dosing. Higher-dose cohorts may provide early insights into target engagement to inform future development, with readouts expected later this year,” said Dr. Ed Tucker, Chief Medical and Development Officer.
Appointment of Bernard Coulie as Chair of the Board
Dr. Coulie joins Atisama at a pivotal moment, as RB042 advances through early clinical development and the Company prepares for its next phase of growth.
Dr. Coulie currently serves as President and CEO of Pliant Therapeutics (NASDAQ: PLRX), a clinical-stage biopharmaceutical company focused on the development of integrin-based therapies, and holds board positions at several global biotech companies. His career includes senior executive roles at Johnson & Johnson and Actogenix. He has founded and led companies across a range of therapeutic areas, with particular expertise in pulmonary disease, directly relevant to Atisama’s lead clinical programme.
As Chair, Dr. Coulie brings deep governance experience and operational leadership to the Atisama Board, with clinical, scientific and commercial acumen that aligns directly with the Company’s mission.
